ESTRO 2024 - Abstract Book

S2183

Clinical - Upper GI

ESTRO 2024

Between September 2017 and July 2023 clinical information was retrospectively collected for 32 patients (38 lesions) with primary liver tumors treated with SBRT in our center. After abdominal dampening with thermoplastic mask and 4DCT-simulation with contrast or expiration CT with and without contrast and MRI fusion, patients received SBRT doses of 30-60 Gy in 3-5 fractions in Synergy®, Infinity® LINAC and Cyberknife®.

Results:

Median age was 67 years (43-93). 28/32 patients had hepatocellular carcinoma, 3/32 patients had cholangiocarcinoma and 1/32 patient had sarcoma. 15 patients had Child Pugh A5, 10 patients had Child Pugh A6, 7 patients Child Pugh B7 and 1 patients Child Pugh B8 pretreatment. All patients had received other previous local treatments (RF, TACE, TARE and/or surgery). The median OS from diagnosis was 40.5 months (range, 1-100 months). Median PFS after SBRT was 19 months (range, 1-73 meses). The local PFS at 12 and 24 months was 93,75% (2/32) and 90,62% (3/32). The level of Child Pugh at 3 months after SBRT worsened in 6 patients and improved in 2 patients, and remained unchanged in the remaining patients. The pretreatment ALBI value was a predictor of worsening in 2 patients with G3, and 2 with G2. The univariate model indicated that AFP level was a significant independent predictor of liver toxicity (p=0,037).

Conclusion:

SBRT is a safe treatment for patients with primary liver tumors. In particular, AFP level is an independent predictor of toxicity. These data establish hypotheses for further studies.

Keywords: SBRT, hepatocellular carcinoma, toxicity

1031

Digital Poster

Predictive factors for distant relapse in patients treated with SBRT in liver metastases

Carolina de la Pinta 1,2 , David Sevillano 1 , Juan David García 1 , Desirée Valencia 1 , Abel Sacristán 1 , Sara Barrio 1 , Esther Montero 1 , Sonsoles Sancho 1 1 Ramon y Cajal Hospital, Radiation Oncology Department, Madrid, Spain. 2 IRYCIS, Biomarkers and therapeutic targets group, Madrid, Spain

Purpose/Objective:

The treatment of liver metastases with stereotactic body radiotherapy (SBRT) is increasingly widespread in oligometastases and oligoprogression scenarios, however, early distant progression is frequent and limits its usefulness. We evaluated clinical predictive factors for early distant progression in patients with liver metastases who underwent SBRT in our institution.